Penumbra Inc

Financials

Cash from operating activities -33.24 M9.5 M-55.66 M97.33 M168.48 M238.66 M 238.66 M Cash from investing activities -104.15 M-21.73 M54.79 M-16.08 M77.62 M-404.59 M -404.59 M Cash from financing activities 134.92 M836 K11.62 M16.2 M-87.01 M26.53 M 26.53 M Free cash flow -58 M-11.68 M-74.96 M82.12 M147.3 M174.93 M 174.93 M

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm. In January 2026, Boston Scientific announced it would acquire Penumbra in a $15 billion cash and stock deal. The deal was expected to close by yearend.

PEN

Financials

Penumbra Inc

Notícias

Estudo da Penumbra mostra melhores resultados para embolia pulmonar

3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)

Diretor da Penumbra vende US$ 32.822 em ações

Penumbra (PEN) Down 1.6% Since Last Earnings Report: Can It Rebound?

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates

UBS reitera classificação neutra para Penumbra com confiança em trombectomia

UBS reiterates Penumbra stock rating on thrombectomy confidence

Fewer Deals, Bigger Stakes: Deciphering The 2026 M&A Landscape And The Rise Of Megadeals

PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise

UBS mantém classificação neutra para Penumbra com preço-alvo de US$ 374

UBS reiterates Neutral on Penumbra stock, keeps $374 target